- Home
- MGNX vs BRT Comparison
MGNX vs BRT Comparison
Compare MGNX & BRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGNX | BRT |
|---|---|---|
| Founded | 2000 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.4M | 252.0M |
| IPO Year | 2013 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MGNX | BRT |
|---|---|---|
| Price | $2.35 | $12.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $8.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 923.0K | 52.3K |
| Earning Date | 11-16-2026 | 11-17-2026 |
| Dividend Yield | N/A | ★ 7.75% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | $97,028,000.00 |
| Revenue This Year | N/A | $1.10 |
| Revenue Next Year | N/A | $7.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.46 |
| 52 Week Low | $1.29 | $12.82 |
| 52 Week High | $5.08 | $15.63 |
Technical Indicators
Market Signals| Indicator | MGNX | BRT |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 43.92 |
| Support Level | $1.71 | N/A |
| Resistance Level | $3.46 | $14.91 |
| Average True Range (ATR) | 0.31 | 0.37 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 26.44 | 22.28 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.